Vektor Medical

What Vektor Medical does

Vektor Medical is a San Diego-based, privately held medical device company founded in 2017-2018 as a spin-out from the University of California, San Diego. Its sole commercial product, vMap, is an FDA-cleared and CE marked AI-based computational platform that transforms standard 12-lead ECG data into non-invasive 2D and 3D four-chamber cardiac maps in under a minute, supporting electrophysiologists in localizing arrhythmia sources prior to and during catheter ablation procedures.

The platform is built on proprietary forward-solution computational modeling developed at UCSD and protected by 11+ issued US patents. vMap is indicated for 7 arrhythmias (atrial fibrillation, ventricular tachycardia, fibrillation, premature complexes including PACs/PVCs, orthodromic AV reentrant tachycardia) and 2 pacing types, with a December 2025 FDA clearance extending capability to atrial flutter. The system runs as FDA-cleared Software as a Medical Device (SaMD) and supports ECG streaming, 3D model import, and EP system integration. Clinical validation includes a blinded multicenter study showing 97.3% mapping accuracy, 91.1% epicardial/endocardial VT classification accuracy, and prospective outcome studies demonstrating 80% one-year arrhythmia-free survival in hemodynamically unstable VT versus 43% in controls.

Vektor monetizes vMap through enterprise software licensing and per-procedure economics to hospitals and electrophysiology labs, distributed by a direct field sales team supported by Clinical Specialists. The company sells primarily in the United States (30+ hospitals) and expanded into Europe following October 2025 CE Mark certification. Reimbursement is supported by a Category III CPT code effective July 2024. The company has raised a $25M oversubscribed Series A led by Solas BioVentures and TVM Capital Life Science and reports 2,500+ procedures performed worldwide.

Name

Vektor Medical

Legal name

Vektor Medical, Inc.

Website

https://vektormedical.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Vektor Medical is a San Diego-based medical device company whose FDA-cleared vMap platform uses AI to convert standard 12-lead ECG data into non-invasive 3D arrhythmia maps, helping electrophysiologists at hospitals and EP labs plan and execute cardiac ablations.

Ownership category

akta.pro rank

Product category

Cardiac Electrophysiology Software / Arrhythmia Mapping Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Measuring & Controlling Devices, Nec (3829)

akta.pro primary industry

Electrophysiology Mapping & Ablation Systems (HLAHAFAD)

akta.pro secondary industries

Electrophysiology (Heart Rhythm) (HLAKABAC), Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)

Keywords

• Cardiac arrhythmia mapping
• Electrophysiology software
• ECG analysis
• AI medical devices
• Catheter ablation planning

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Medical Device Software Licensing: vMap is sold as a medical device with software components, FDA cleared for commercial use in the U.S. and CE marked for use in the EU. Revenue generated through hospital/EP lab licensing and clinical usage.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Vektor Medical develops and sells vMap, an FDA-cleared and CE marked AI-based non-invasive cardiac arrhythmia analysis system that transforms standard 12-lead ECG data into 3D arrhythmia source maps in under a minute. The software supports electrophysiology workflows for atrial fibrillation, ventricular tachycardia, atrial flutter, PACs/PVCs, AV reentrant tachycardia, and pacing, enabling rapid non-invasive arrhythmia localization to guide catheter ablation procedures. vMap is deployed as a Software as a Medical Device (SaMD) to hospitals and EP labs in the US and Europe.

Product overview

Vektor Medical offers a single unified product: vMap, an FDA-cleared and CE marked AI-based arrhythmia analysis platform. The system uses standard 12-lead ECG data as input to generate non-invasive, four-chamber cardiac maps that localize arrhythmia sources in under a minute. vMap supports clinical workflows across atrial fibrillation ablation, ventricular tachycardia ablation, and atrial flutter evaluation, enabling physicians to rapidly identify ablation targets and optimize procedural efficiency.

Differentiator

Problem solved

Functional benefit

Products and services

• vMap FDA-cleared and CE marked AI-based non-invasive arrhythmia analysis system that transforms standard 12-lead ECG data into 3D arrhythmia source maps in under a minute. Indicated for 7 arrhythmias (atrial fibrillation, ventricular tachycardia, fibrillation, PACs, PVCs, orthodromic AV reentrant tachycardia) and 2 pacing types, providing four-chamber cardiac insights for electrophysiologists performing catheter ablation procedures at hospitals and EP labs.
• Next-Generation vMap Next-generation vMap extending the vMap platform with atrial flutter mapping, ECG streaming, enhanced EP system connectivity, 3D model import and visualization tools, and SaMD deployment for electrophysiology workflows.

Quantifiable outcome

• 80% one-year arrhythmia-free survival in vMap-guided unstable VT ablation vs 43% conventional (EP Europace 2026)
• +7 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

One partnership is on record.

• BSIcoreOthers · 7 October 2025BSI served as the Notified Body for CE Mark certification of vMap under EU Medical Device Regulation. CE Mark enables commercialization across European markets.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Biosense Webster (Johnson & Johnson): Biosense Webster's CARTO 3 system is the dominant invasive 3D electroanatomical mapping platform used in cardiac ablation. Direct overlap with vMap's target end users (electrophysiologists performing ablation), but competing with established workflow integration in EP labs.
• Boston Scientific (EP franchise incl. RHYTHMIA): Boston Scientific's EP portfolio (including the RHYTHMIA HDx mapping system) targets the same ablation procedures as vMap. They are a broad incumbent with capital, established sales channels, and an installed hospital base across the US and EU.
• Abbott (EnSite X): Abbott's EnSite X is a widely used 3D cardiac mapping system that competes for the same pre-procedure and intra-procedure planning workflow as vMap in hospital EP labs globally.

Emerging players

• Volta Medical: Volta Medical builds AI-driven decision-support software for cardiac ablation, including persistent AF. Direct emerging AI peer using computational analytics to improve ablation outcomes — comparable customer (EP labs) and comparable artificial-intelligence-driven workflow for arrhythmia care.
• BioSig Technologies: BioSig Technologies developed the PURE EP System, a non-invasive signal-processing platform for cardiac ablation procedures. Closest direct emerging peer to vMap, focused on improving procedural signal fidelity for electrophysiology procedures.
• Acutus Medical: Acutus Medical developed AcQMap, a non-invasive high-resolution imaging and mapping system for arrhythmia ablation. Comparable emerging peer targeting the same electrophysiology procedural workflow using novel mapping technology.
• CathVision: CathVision builds EP recording and analytics systems (EP-Workmate, EP-Reporter). Adjacent emerging peer selling into the same electrophysiology labs as Vektor, focused on procedural signal acquisition and cloud analytics.
• SentiAR: SentiAR develops augmented-reality visualization for cardiac ablation procedures. Emerging peer using advanced visualization to assist electrophysiologists, conceptually similar to vMap's 4-chamber 3D visualization approach for arrhythmia localization.
• iRhythm Technologies: iRhythm's Zio cardiac monitoring platform uses AI on ambulatory ECG data to detect arrhythmias. Overlap with vMap in applying AI to ECG data for arrhythmia characterization, but operating in monitoring/diagnosis rather than procedural mapping.
• HeartBeam: HeartBeam applies AI to synthesized 12-lead ECG signals for cardiac diagnostics, including arrhythmia detection. Comparable emerging AI/ECG peer with similar architectural approach of deriving cardiac insight from standard ECG data.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vektormedical/jobs
• Xx.com/VektorMedical

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles24 records

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vektor Medical